{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:29:42Z","timestamp":1789759782769,"version":"4.0.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2016,3,11]],"date-time":"2016-03-11T00:00:00Z","timestamp":1457654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23 AR059677"],"award-info":[{"award-number":["K23 AR059677"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24 AR055989"],"award-info":[{"award-number":["K24 AR055989"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P60 AR047782"],"award-info":[{"award-number":["P60 AR047782"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AR056215"],"award-info":[{"award-number":["R01 AR056215"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000965","name":"American Federation for Aging Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000965","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000909","name":"John A. Hartford Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000909","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004426","name":"Atlantic Philanthropies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004426","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\u2003<\/jats:title>\n                    <jats:p>The U.S. Food and Drug Administration (FDA) issued several announcements related to potential risk of bisphosphonates including osteonecrosis of the jaw (2005), atrial fibrillation (2007), and atypical femur fracture (2010). We aimed to evaluate the impact of three FDA drug safety announcements on the use of bisphosphonates in patients with hip fracture using claims data from a U.S. commercial health plan (2004-2013). We calculated the proportion of patients in each quarter who received a bisphosphonate or other osteoporosis medication in the 6 months following hospitalization for hip fracture. Segmented logistic regression models examined the time trends. Among 22,598 patients with hip fracture, use of bisphosphonate decreased from 15% in 2004 to 3% in the last quarter of 2013. Prior to the 2007 announcement, there was a 4% increase in the odds of bisphosphonate use every quarter (OR 1.04; 95% CI, 1.02 to 1.07). After the 2007 announcement, there was a 4% decrease in the odds of bisphosphonate use (OR 0.96; 95% CI, 0.93 to 0.99) every quarter. The announcement in 2007 was associated with a significant decline in the rate of change of bisphosphonate uses over time (p\u2009&amp;lt;\u20090.001), but no impact on other osteoporosis medication use (p\u2009=\u20090.2). After the 2010 announcement, the odds of bisphosphonate use continued to decrease by 4% (OR 0.96; 95% CI, 0.94 to 0.98) each quarter and the odds of other osteoporosis medication use remained stable over time (OR 0.99; 95% CI, 0.96 to 1.02). The FDA safety announcement related to atrial fibrillation in 2007 was significantly associated with a decrease in bisphosphonate use among patients with hip fracture. \u00a9 2016 American Society for Bone and Mineral Research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jbmr.2832","type":"journal-article","created":{"date-parts":[[2016,3,12]],"date-time":"2016-03-12T14:22:23Z","timestamp":1457792543000},"page":"1536-1540","source":"Crossref","is-referenced-by-count":98,"title":["Impact of the U.S. Food and Drug Administration's Safety-Related Announcements on the Use of Bisphosphonates After Hip Fracture"],"prefix":"10.1093","volume":"31","author":[{"given":"Seoyoung C","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Immunology and AllergyBrigham and Women's HospitalBostonMAUSA"},{"name":"Division of Pharmacoepidemiology and PharmacoeconomicsBrigham and Women's HospitalBostonMAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Gerontology DivisionBeth Israel Deaconess Medical CenterBostonMAUSA"},{"name":"Division of Pharmacoepidemiology and PharmacoeconomicsBrigham and Women's HospitalBostonMAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Mogun","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and PharmacoeconomicsBrigham and Women's HospitalBostonMAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Eddings","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and PharmacoeconomicsBrigham and Women's HospitalBostonMAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M","family":"Polinski","sequence":"additional","affiliation":[{"name":"CVS CaremarkWoonsocketRIUSA"},{"name":"Division of Pharmacoepidemiology and PharmacoeconomicsBrigham and Women's HospitalBostonMAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M","family":"Franklin","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and PharmacoeconomicsBrigham and Women's HospitalBostonMAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H","family":"Solomon","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Immunology and AllergyBrigham and Women's HospitalBostonMAUSA"},{"name":"Division of Pharmacoepidemiology and PharmacoeconomicsBrigham and Women's HospitalBostonMAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,3,11]]},"reference":[{"key":"2024021014183741400_jbmr2832-bib-0001","year":"2013"},{"key":"2024021014183741400_jbmr2832-bib-0002","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1002\/jbmr.2202","article-title":"Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011","volume":"29","author":"Solomon","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2024021014183741400_jbmr2832-bib-0003","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.amjmed.2015.01.014","article-title":"Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study","volume":"128","author":"Kim","year":"2015","journal-title":"Am J Med"},{"key":"2024021014183741400_jbmr2832-bib-0004"},{"key":"2024021014183741400_jbmr2832-bib-0005"},{"issue":"1","key":"2024021014183741400_jbmr2832-bib-0006","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.joms.2013.06.221","article-title":"Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate","volume":"72","author":"Ulmner","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"2024021014183741400_jbmr2832-bib-0007","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00198-012-2042-6","article-title":"Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges","volume":"24","author":"Solomon","year":"2013","journal-title":"Osteoporos Int"},{"issue":"18","key":"2024021014183741400_jbmr2832-bib-0008","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"2024021014183741400_jbmr2832-bib-0009","doi-asserted-by":"crossref","first-page":"e0122646","DOI":"10.1371\/journal.pone.0122646","article-title":"Bisphosphonates and risk of cardiovascular events: a meta-analysis","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"2024021014183741400_jbmr2832-bib-0010","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/jbmr.1719","article-title":"Incidence of atypical nontraumatic diaphyseal fractures of the femur","volume":"27","author":"Dell","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2024021014183741400_jbmr2832-bib-0011","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/jbmr.1893","article-title":"Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis","volume":"28","author":"Gedmintas","year":"2013","journal-title":"J Bone Miner Res"},{"key":"2024021014183741400_jbmr2832-bib-0012","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/9781118707999.ch11","volume-title":"Textbook of pharmacoepidemiology","author":"Strom","year":"2006"},{"issue":"7","key":"2024021014183741400_jbmr2832-bib-0013","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0895-4356(92)90047-Q","article-title":"Identification of fractures from computerized Medicare files","volume":"45","author":"Ray","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"2024021014183741400_jbmr2832-bib-0014","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","article-title":"A combined comorbidity score predicted mortality in elderly patients better than existing scores","volume":"64","author":"Gagne","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"2024021014183741400_jbmr2832-bib-0015","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1002\/jbmr.1698","article-title":"Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention","volume":"27","author":"Eisman","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024021014183741400_jbmr2832-bib-0016","first-page":"124","article-title":"The second hip fracture in osteoporotic patients: not only an orthopaedic matter","volume":"10","author":"Scaglione","year":"2013","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"11","key":"2024021014183741400_jbmr2832-bib-0017","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00198-003-1460-x","article-title":"The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies","volume":"14","author":"Colon-Emeric","year":"2003","journal-title":"Osteoporos Int"},{"key":"2024021014183741400_jbmr2832-bib-0018","doi-asserted-by":"crossref","first-page":"nihpa40967","DOI":"10.1056\/NEJMoa074941","article-title":"for the HORIZON Recurrent Fracture Trial. Zoledronic acid in reducing clinical fracture and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"2024021014183741400_jbmr2832-bib-0019","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00198-012-2024-8","article-title":"Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients-a nationwide register-based open cohort study","volume":"24","author":"Bondo","year":"2013","journal-title":"Osteoporos Int"},{"issue":"19","key":"2024021014183741400_jbmr2832-bib-0020","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa1001086","article-title":"for the Fracture Intervention Trial and HORIZON Pivotal Fracture Trial Steering Committees. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur","volume":"362","author":"Black","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.2832","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.2832","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/31\/8\/1536\/56650176\/jbmr2832.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/31\/8\/1536\/56650176\/jbmr2832.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T10:56:07Z","timestamp":1710327367000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/31\/8\/1536-1540\/7605289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,11]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,3,11]]},"published-print":{"date-parts":[[2016,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.2832","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,8,1]]},"published":{"date-parts":[[2016,3,11]]}}}